AB Science today provides an update on its masitinib platform

Core Insights - AB Science provided an update on its masitinib platform, highlighting its potential in treating various neurological diseases, including amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), and Alzheimer's disease [1][5]. Group 1: Masitinib Platform Developments - A new confirmatory study (AB23005) will be initiated, simplifying enrollment and targeting the best responders for masitinib, in line with recommendations from the FDA and EMA [5]. - The design of the study has been validated and authorized by both the FDA and EMA, securing a pathway to registration with these agencies [5]. - The first study (AB10015) generated strong hypotheses regarding patient survival, showing a significant +12 months survival benefit and a long-term follow-up indicating that 53% of patients survived more than 5 years, with a +36 months benefit over ENCLALS predictions [5]. Group 2: Mechanism of Action and Efficacy - Masitinib's mechanism of action targets microglia and mast cells, which are crucial in the innate immune response, enhancing its efficacy in treating neurological diseases [5]. - The drug has shown competitive results compared to BTK inhibitors in terms of EDSS progression, despite the populations being non-comparable [5]. - Masitinib is the only drug that has generated positive results in moderate Alzheimer's disease and could potentially be combined with biologics for early and mild cases [5]. Group 3: Market Potential and Intellectual Property - The unmet medical need in ALS, MS, and Alzheimer's disease is immense, with potential sales exceeding billions in each indication [5]. - Masitinib's intellectual property rights are secured through a use patent until 2037 in ALS and up to 2041 in MS and Alzheimer's, along with orphan drug status in ALS and data protection of 10 years in Europe and 8 years in the USA [5]. Group 4: Company Overview - AB Science, founded in 2001, specializes in the research, development, and commercialization of protein kinase inhibitors (PKIs) targeting diseases with high unmet medical needs [6][7]. - The company is headquartered in Paris, France, and is listed on Euronext Paris [7].